Research progress of microRNA in renal cell carcinoma

Though the adjuvant sunitinib or sorafenib has been proved in treatment to patients with renal cell carcinoma (RCC), the benefts from drug therapies are limited due to the highly malignant behavior of RCC. The microRNAs (miRNA), as inhibitors or activators in RCC patients，is involved in the signal pathways (like VHL/cMET) in RCC. This review elaborates current studies of the role that miRNAs plays in RCC，including expression level and specifc signal pathways between miRNAs and RCC. Besides, we summarize the clinical application (such as detection, prognosis prediction and treatment) of miRNAs in RCC patients.